Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911995074> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2911995074 endingPage "1482" @default.
- W2911995074 startingPage "1482" @default.
- W2911995074 abstract "Recent studies have shown that hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy (SIB-IMRT) provided certain survival benefits over other fractionation methods for high-grade gliomas. However, the best hypofractionation mode and its efficacy have not been confirmed. The purpose of this study was to investigate the maximum tolerated dose (MTD) of hypofractionated SIB-IMRT with stepwise escalating doses combined with temozolomide (TMZ) for treating malignant gliomas.The patients received concurrent postoperative radiotherapy and chemotherapy. SIB-IMRT was adopted to increase the dose both in the surgical cavity and residual tumor (planning target volume 1). The dose at each fraction was gradually increased from 2.8 Gy/f (total of 20 times), with an escalating dose interval of 0.4 Gy. The planning target volume 2 involved the 2 cm region around surgical cavity, and residual tumor remained unchanged, with 2.5 Gy each time and a total of 50 Gy/20f. TMZ was administered with a dose of 75 mg/m2/day during radiotherapy. Adjuvant TMZ was given at 150-200 mg/m2/day for 5 days every 28 days. A total of 16 patients were enrolled.Three patients exhibited dose-limiting toxicity (DLT), two cases reported Grade 3 headache in the 3.6 Gy/f and 4 Gy/f dose groups, and one patient developed persistent seizures attacks in the 4 Gy/f dose group. Therefore, 4 Gy/f was considered the DLT and the lower dose level of 3.6 Gy/f was regarded as the MTD in the study, with tolerable adverse reactions. The median overall survival (OS) and median progression-free survival (PFS) in this study were 19 and 16 months, respectively. The 1- and 2-year OS and PFS were 86.7%, 31.0% and 73.7%, 26.7%, respectively.It showed that the treatment of high-grade gliomas with hypofractionated SIB-IMRT combined with TMZ had an MTD of 3.6 Gy/f (72 Gy/20f). In addition, the results preliminarily showed improved survival." @default.
- W2911995074 created "2019-02-21" @default.
- W2911995074 creator A5001420405 @default.
- W2911995074 creator A5008964526 @default.
- W2911995074 creator A5012074247 @default.
- W2911995074 creator A5022919699 @default.
- W2911995074 creator A5030054597 @default.
- W2911995074 creator A5047498218 @default.
- W2911995074 creator A5059343541 @default.
- W2911995074 creator A5064528726 @default.
- W2911995074 creator A5082585802 @default.
- W2911995074 date "2018-01-01" @default.
- W2911995074 modified "2023-10-14" @default.
- W2911995074 title "Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial" @default.
- W2911995074 cites W2141495000 @default.
- W2911995074 doi "https://doi.org/10.4103/jcrt.jcrt_51_18" @default.
- W2911995074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30589027" @default.
- W2911995074 hasPublicationYear "2018" @default.
- W2911995074 type Work @default.
- W2911995074 sameAs 2911995074 @default.
- W2911995074 citedByCount "1" @default.
- W2911995074 countsByYear W29119950742020 @default.
- W2911995074 crossrefType "journal-article" @default.
- W2911995074 hasAuthorship W2911995074A5001420405 @default.
- W2911995074 hasAuthorship W2911995074A5008964526 @default.
- W2911995074 hasAuthorship W2911995074A5012074247 @default.
- W2911995074 hasAuthorship W2911995074A5022919699 @default.
- W2911995074 hasAuthorship W2911995074A5030054597 @default.
- W2911995074 hasAuthorship W2911995074A5047498218 @default.
- W2911995074 hasAuthorship W2911995074A5059343541 @default.
- W2911995074 hasAuthorship W2911995074A5064528726 @default.
- W2911995074 hasAuthorship W2911995074A5082585802 @default.
- W2911995074 hasBestOaLocation W29119950741 @default.
- W2911995074 hasConcept C126322002 @default.
- W2911995074 hasConcept C126894567 @default.
- W2911995074 hasConcept C155806632 @default.
- W2911995074 hasConcept C2777389519 @default.
- W2911995074 hasConcept C29730261 @default.
- W2911995074 hasConcept C2989005 @default.
- W2911995074 hasConcept C509974204 @default.
- W2911995074 hasConcept C71924100 @default.
- W2911995074 hasConceptScore W2911995074C126322002 @default.
- W2911995074 hasConceptScore W2911995074C126894567 @default.
- W2911995074 hasConceptScore W2911995074C155806632 @default.
- W2911995074 hasConceptScore W2911995074C2777389519 @default.
- W2911995074 hasConceptScore W2911995074C29730261 @default.
- W2911995074 hasConceptScore W2911995074C2989005 @default.
- W2911995074 hasConceptScore W2911995074C509974204 @default.
- W2911995074 hasConceptScore W2911995074C71924100 @default.
- W2911995074 hasIssue "7" @default.
- W2911995074 hasLocation W29119950741 @default.
- W2911995074 hasLocation W29119950742 @default.
- W2911995074 hasOpenAccess W2911995074 @default.
- W2911995074 hasPrimaryLocation W29119950741 @default.
- W2911995074 hasRelatedWork W2045641192 @default.
- W2911995074 hasRelatedWork W2096287682 @default.
- W2911995074 hasRelatedWork W2128503410 @default.
- W2911995074 hasRelatedWork W2150741177 @default.
- W2911995074 hasRelatedWork W2182919525 @default.
- W2911995074 hasRelatedWork W2293453490 @default.
- W2911995074 hasRelatedWork W2367829007 @default.
- W2911995074 hasRelatedWork W2384708512 @default.
- W2911995074 hasRelatedWork W2740663609 @default.
- W2911995074 hasRelatedWork W3194058763 @default.
- W2911995074 hasVolume "14" @default.
- W2911995074 isParatext "false" @default.
- W2911995074 isRetracted "false" @default.
- W2911995074 magId "2911995074" @default.
- W2911995074 workType "article" @default.